Barclays PLC Increases Stock Position in Century Therapeutics, Inc. (NASDAQ:IPSC)

Barclays PLC boosted its stake in Century Therapeutics, Inc. (NASDAQ:IPSC) by 283.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 61,945 shares of the company’s stock after purchasing an additional 45,797 shares during the quarter. Barclays PLC owned about 0.07% of Century Therapeutics worth $106,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of IPSC. SG Americas Securities LLC bought a new stake in shares of Century Therapeutics in the 3rd quarter worth about $27,000. Rhumbline Advisers increased its holdings in shares of Century Therapeutics by 56.0% in the 2nd quarter. Rhumbline Advisers now owns 52,466 shares of the company’s stock worth $134,000 after buying an additional 18,828 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Century Therapeutics by 141.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 75,315 shares of the company’s stock worth $192,000 after buying an additional 44,155 shares during the last quarter. Wellington Management Group LLP bought a new stake in shares of Century Therapeutics in the 3rd quarter worth about $284,000. Finally, Bank of New York Mellon Corp increased its holdings in shares of Century Therapeutics by 110.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 149,000 shares of the company’s stock worth $380,000 after buying an additional 78,088 shares during the last quarter. Hedge funds and other institutional investors own 50.20% of the company’s stock.

Century Therapeutics Trading Up 0.9 %

Shares of NASDAQ:IPSC opened at $1.07 on Thursday. The company has a market capitalization of $90.98 million, a price-to-earnings ratio of -0.58 and a beta of 1.76. Century Therapeutics, Inc. has a 12 month low of $0.95 and a 12 month high of $5.51. The firm’s 50-day moving average is $1.26 and its 200 day moving average is $1.67.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.08. The company had revenue of $0.79 million for the quarter, compared to the consensus estimate of $0.47 million. Century Therapeutics had a negative net margin of 4,837.73% and a negative return on equity of 61.66%. During the same period in the prior year, the firm posted ($0.55) EPS. As a group, equities analysts forecast that Century Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on IPSC shares. HC Wainwright reduced their target price on shares of Century Therapeutics from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Wednesday, November 6th. Chardan Capital reduced their target price on shares of Century Therapeutics from $17.00 to $11.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Finally, Piper Sandler reduced their target price on shares of Century Therapeutics from $12.00 to $4.00 and set an “overweight” rating on the stock in a report on Monday, December 30th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Century Therapeutics currently has a consensus rating of “Buy” and an average price target of $10.00.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.